The prodigiosins, proapoptotic drugs with anticancer properties

Biochemical Pharmacology

Volumn 66, Issue 8, 2003, Pages 1447-1452

  Pérez Tomás, Ricardo ^a   Montaner, Beatriz ^a   Llagostera, Esther ^a   Soto Cerrato, Vanessa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

c jun N terminal kinase; cPrG HCl; Cycloprodigiosin hydrochloride; Double strand; ds; ERK; Extracellular signal regulated kinase; IC50; Inhibitory concentration 50 ; Jak3; Janus kinase 3; JNK; MAPK; Mitogen activated protein kinase; PG

Indexed keywords

2 METHYL 3 PENTYLPRODIGIOSINE; 2 UNDECYL 6 METHOXYPRODIGIOSINE; ANTINEOPLASTIC AGENT; CYCLOPRODIGIOSIN; CYTOTOXIC AGENT; METACYCLOPRODIGIOSIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PNU 156804; PRODIGIOSIN; PRODIGIOSIN DERIVATIVE; PROTEIN KINASE C; PROTON PUMP INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; DNA;

ACIDITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CELL; CANCER CELL DESTRUCTION; CELL PH; CONFERENCE PAPER; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; HUMAN; MOLECULAR BIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CELL CYCLE; METABOLISM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; DNA; HUMANS; PRODIGIOSIN;

EID: 0642283969     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00496-9     Document Type: Conference Paper

References (71)

1. Bennett J.W., Bentley R. Seeing red: the story of prodigiosin. Adv. Appl. Microbiol. 47:2000;1-32.
2. Rook G. Tumours and Coley's toxins. Nature. 357:1992;545.
3. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 72:1975;3666-3670.
4. Pennica D., Nedwin G.E., Hayflick J.S., Seeburg P.H., Derynck R., Palladino M.A., Kohr W.J., Aggarwal B.B., Goeddel D.V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 312:1984;724-729.
5. Wrede F., Rothhass A. Uber das prodigiosin, den roten farbstoff des Bacillus prodigiosus. Hoppe Seyler's Z. Chem. Ber. 226:1934;95.
6. Burger S.R., Bennett J.W. Droplet enrichment factors of pigmented and nonpigmented Serratia marcescens: possible selective function for prodigiosin. Appl. Environ. Microbiol. 50:1985;487-490.
7. Matsuyama T., Murakami T., Fujita M., Fujita S., Yano I. Extracellular vesicle formation and biosurfactant production by Serratia marcescens. J. Gen. Microbiol. 132:1986;865-875.
8. Castro A.J. Antimalarial activity of prodigiosin. Nature. 13:1967;903-904.
9. Boger D.L., Patel M. Total synthesis of prodigiosin, prodigiosene, and desmethoxyprodigiosin: Diels-Alder reactions of heterocyclic azadienes and development of an effective palladium(II)-promoted 2,2′-bipyrrole coupling procedure. J. Org. Chem. 53:1988;1405-1415.
10. Kim H.S., Hayashi M., Shibata Y., Wataya Y., Mitamura T., Horii T., Kawauchi K., Hirata H., Tsuboi S., Moriyama Y. Cycloprodigiosin hydrochloride obtained from Pseudoalteromonas denitrificans is a potent antimalarial agent. Biol. Pharm. Bull. 22:1999;532-534.
11. Melo P.S., Durán N., Haun M. Cytotoxicity of prodigiosin and benznidazole on V79 cells. Toxicol. Lett. 116:2000;237-242.
12. Nakamura A., Nagai K., Ando K., Tamura G. Selective suppression by prodigiosin of the mitogenic response of murine splenocytes. J. Antibiot. 8:1986;1155-1159.
13. Nakamura A., Magae J., Tsuji R.F., Yamasaki M., Nagai K. Suppression of cytotoxic T cell induction in vivo by prodigiosin 25-C. Transplantation. 47:1989;1013-1016.
14. Tsuji R.F., Yamamoto M., Nakamura A., Kataoka T., Magae J., Nagai K., Yamasaki M. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. J. Antibiot. 43:1990;1293-1301.
15. Tsuji R.F., Magae J., Jamashita M., Nagai K., Yamasaki M. Immunomodulating properties of prodigiosin 25-C, an antibiotic which preferentially suppresses induction of cytotoxic T cells. J. Antibiot. 45:1992;1295-1302.
16. +-ATPase. Biosci. Biotechnol. Biochem. 59:1995;1417-1421.
17. Magae J., Miller M.W., Nagai K., Shearer G.M. Effect of metacycloprodigiosin, an inhibitor of killer T cells on murine skin and heart transplants. J. Antibiot. 49:1996;86-90.
18. Songia S., Mortellaro A., Taverna S., Fornasiero C., Scheiber E.A., Erba E., Colotta F., Mantovani A., Isetta A.M., Golay J. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes. J. Immunol. 158:1997;3987-3995.
19. Kawauchi K., Shibutani K., Yagisawa H., Kamata H., Nakatsuji S., Anzai H., Yokoyama Y., Ikegami Y., Moriyama Y., Hirata H. A possible immunosuppressant, cycloprodigiosin hydrochloride, obtained from Pseudoalteromonas denitrificans. Biochem. Biophys. Res. Commun. 237:1997;543-547.
20. Han S.B., Kim H.M., Kim Y.H., Lee C.W., Jang E.S., Son K.H., Kim S.U., Kim Y.K. T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. Int. J. Immunopharmacol. 20:1998;1-13.
21. Lee M.H., Yamashita M., Tsuji R.F., Yamasaki M., Kataoka T., Magae J., Nagai K. Suppression of T cell stimulating function of allogeneic antigen presenting cells by prodigiosin 25-C. J. Antibiot. 51:1998;92-94.
22. Mortellaro A., Songia S., Gnocchi P., Ferrari M., Fornasiero C., D'Alessio R., Isetta A., Colotta F., Golay J. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation. J. Immunol. 162:1999;7102-7109.
23. + mature cytotoxic T cells by inhibitors of acidification of intracellular organelles. Immunology. 99:2000;243-248.
24. Azuma T., Watanabe N., Yagisawa H., Hirata H., Iwamura M., Kobayashi Y. Induction of apoptosis of activated murine splenic T cells by cycloprodigiosin hydrochloride, a novel immunosuppressant. Immunopharmacology. 46:2000;29-37.
25. Nakai K., Hamada Y., Kato Y., Yamamoto D., Hirata H., Hioki K. Cycloprodigiosin hydrochloride as an immunosuppressant in rat small bowel transplantation. Transplant. Proc. 32:2000;1324-1325.
26. Fürstner A., Grabowski J., Lehmann C.W., Kataola T., Nagai K. Synthesis and biological evaluation of nonylprodigiosin and macrocyclic prodigiosin analogues. Chem. Biochem. 2:2001;60-68.
27. Han S.B., Park S.H., Jeon Y.J., Kim Y.K., Kim H.M., Yang K.H. Prodigiosin blocks T cell activation by inhibiting interleukin-2Rα expression and delays progression of autoimmune diabetes and collagen-induced arthritis. J. Pharm. Exp. Ther. 299:2001;415-425.
28. Stepkowski S.M., Erwin-Cohen R.A., Behbod F., Wang M.E., Qu X., Tejpal N., Nagy Z.S., Kahan B.D., Kirken R.A. Selective inhibitor of janus tyrosine kinase 3 PNU156804 prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 99:2002;680-689.
29. Montaner B., Navarro S., Piqué M., Vilaseca M., Martinell M., Giralt E., Gil J., Pérez-Tomás R. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br. J. Pharmacol. 131:2000;585-593.
30. Montaner B., Pérez-Tomás R. Prodigiosin-induced apoptosis in human colon cancer cells. Life Sci. 68:2001;2025-2036.
31. Díaz-Ruíz C., Montaner B., Pérez-Tomás R. Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1. Histol. Histopathol. 16:2001;415-421.
32. Pérez-Tomás R., Montaner B. Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. Histol. Histopathol. 18:2003;379-385.
33. Campàs C., Dalmau M., Montaner B., Barragán M., Bellosillo B., Colomer D., Pons G., Pérez-Tomás R., Gil J. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukaemia. Leukemia. 17:2003;746-750.
34. D'Alessio R., Rossi A. Short synthesis of undecylprodigiosine. A new route to 2,2′-bipyrrolyl-pyrromethene systems. Synlett. 6:1996;513-514.
35. D'Alessio R., Bargiotti A., Carlini O., Colotta F., Ferrari M., Gnocchi P., Isetta A., Mongelli N., Motta P., Rossi A., Rossi M., Tibolla M., Vanotti E. Synthesis and immunosuppressive activity of novel prodigiosin derivatives. J. Med. Chem. 43:2000;2557-2565.
36. Cameron R, Feuer G. Molecular cellular and tissue reactions of apoptosis and their modulation by drugs. In: Cameron R, Feuer G, editors. Handbook of experimental pharmacology. Berlin: Springer-Verlag; 2000. p. 37-57.
37. - symporter, induces apoptosis in human breast cancer cell lines. J. Cancer Res. Clin. Oncol. 126:2000;191-197.
38. - symporter induces apoptosis and differentiation in HL-60 cells. Int. J. Cancer. 88:2000;121-128.
39. - symporter, induces apoptosis in human colon cancer cell lines in vitro. Oncol. Rep. 8:2001;821-824.
40. - symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology. 30:1999;894-902.
41. - symport. Biochem. J. 334:1998;731-741.
42. Arends M.J., Wyllie A.H. Apoptosis: mechanisms and roles in pathology. Int. Rev. Esp. Pathol. 32:1991;223-256.
43. Thangaraju M., Sharma K., Liu D., Shen S.H., Srikant C.B. Interdependent regulation of intracellular acidification and SHP-1 in apoptosis. Cancer Res. 59:1999;1649-1654.
44. Matsuyama S., Llopis J., Deveraux Q.L., Tsien R.Y., Reed J.C. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat. Cell Biol. 2:2000;318-325.
45. - symporters that uncouple proton translocators. J. Biol. Chem. 273:1998;21455-21462.
46. - requirement for inhibition of vacuolar acidification by cycloprodigiosin in situ. Plant Cell Physiol. 41:2000;857-863.
47. - symport activity. J. Biochem. 124:1998;547-556.
48. +-ATPase, inhibits vacuolar acidification and effects glycoprotein processing. FEBS Lett. 359:1995;53-59.
49. Shrode L.D., Tapper H., Grinstein S. Role of intracellular pH in proliferation transformation and apoptosis. J. Bioenerg. Biomembr. 29:1997;393-399.
50. Hussain S.P., Harris C.C. Molecular epidemiology of human cancer: contribution of mutation spectra studies for tumor suppressor genes. Cancer Res. 58:1998;4023-4037.
51. Kirsch D.G., Kastan M.B. Tumor suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol. 16:1998;3158-3168.
52. Brown J.M., Wouters B.G. Apoptosis p53 and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1999;1391-1399.
53. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104:1999;263-269.
54. Melvin M.S., Tomlinson J.T., Saluta G.R., Kucera G.L., Lindquist N., Manderville R.A. Double-strand DNA cleavage by copper·prodigiosin. J. Am. Chem. Soc. 122:2000;6333-6334.
55. Melvin M.S., Ferguson D.C., Lindquist N., Manderville R.A. DNA binding by 4-methoxypurrolic natural products. Preference for intercalation at AT sites by tambjamine E and prodigiosin. J. Org. Chem. 64:1999;6861-6869.
56. Linder MC. Biochemistry of copper. In: Frieden E, editor. New York: Plenum Press; 1991.
57. Sarkar B. Copper transport and its defect in Wilson disease: characterization of the copper-binding domain of Wilson disease ATPase. J. Inorg. Biochem. 79:2000;187-191.
58. Theophanides T., Anastassopoulou J. Copper and carcinogenesis. Crit. Rev. Oncol. Hematol. 42:2002;57-64.
59. Melvin M.S., Wooton K.E., Rich C.C., Saluta G.R., Kucera G.L., Lindquist N., Manderville R.A. Copper-nuclease efficiency correlates with cytotoxicity for the 4-methoxypyrrolic natural products. J. Inorg. Biochem. 87:2001;129-135.
60. Melvin M.S., Calcutt M.W., Noftle R.E., Manderville R.A. Influence of the a-ring on the redox and nuclease properties of the prodigiosins: importance of the bipyrrole moiety in oxidative DNA cleavage. Chem. Res. Toxicol. 15:2002;742-748.
61. Fürstner A., Grabowski E.J. Studies on DNA cleavage by cytotoxic pyrrole alkaloids reveal the distinctly different behavior of roseophilin and prodigiosin derivatives. Chem. Biochem. 9:2001;706-709.
62. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling. Nat. Genet. 27:2001;247-254.
63. Cano E., Mahadevan L.C. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci. 20:1995;117-122.
64. Mansat V., Laurent G., Levade T., Bettaieb A., Jaffrezou J.P. The protein kinase C activators phorbol esters and phosphatidylserine inhibit neutral sphingomyelinase activation, ceramide generation and apoptosis triggered by daunorubicin. Cancer Res. 57:1997;5300-5304.
65. 2+ dependent endonuclease with protein kinase C as a possible mechanism for cytokine resistance in human renal carcinoma cells. J. Urol. 155:1996;1779-1783.
66. Tomei L.D., Kanter P., Wenner C.E. Inhibition of radiation-induced apoptosis in vitro by tumor promoters. Biochem. Biophys. Res. Commun. 155:1988;324-331.
67. Zanke B.W., Lee C., Arab S., Tannock I.F. Death of tumor cells after intracellular acidification is dependent on stress-activated protein kinases (SAPK/JNK) pathway activation and cannot be inhibited by bcl-2 expression or interleukin 1B-converting enzyme inhibition. Cancer Res. 58:1998;2801-2808.
68. Montaner B., Pérez-Tomás R. Activation of protein kinase C is required for protection of cells against apoptosis induced by the immunossuppresor prodigiosin. Biochem. Pharmacol. 63:2002;463-469.
69. Montaner B., Pérez-Tomás R. The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK/JNK. Toxicol. Lett. 129:2002;93-98.
70. Fullan N.P., Lynch D.L., Ostrow D.H. Effects of bacterial extracts on Chinese hamster cells and rat neoplasms. Microbiol. Lett. 5:1977;157-161.
71. Hannun Y.A. Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1997;1845-1853.